clear cell adenocarcinoma

Summary

Summary: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)

Top Publications

  1. Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;206:271-5 pubmed
    ..No clear cell adenocarcinoma elements were noted in this tumor...
  2. Tsuda H, Ito Y, Ohashi Y, Wong K, Hashiguchi Y, Welch W, et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005;11:6880-8 pubmed
    Patients with ovarian clear cell adenocarcinoma generally have a poor response to combination chemotherapy and have overall poorer prognosis than patients with other histologic types of ovarian cancer...
  3. Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics. 2006;6:5880-90 pubmed
    b>Clear cell adenocarcinoma (CCA) has a highly malignant potential in human epithelial ovarian cancer. The serum CA-125 is widely used as a marker for ovarian cancer, but the level is relatively low in CCA...
  4. Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, et al. Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res. 2006;16:289-97 pubmed
    ..membrane-associated sialidase (NEU3) expression and various clinicopathological factors in ovarian clear cell adenocarcinoma patients...
  5. Mabuchi Y, Yamoto M, Minami S, Umesaki N. The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. Oncol Rep. 2006;16:373-9 pubmed
    The functions of activin, a member of TGF-beta superfamily, in ovarian clear cell adenocarcinoma remain unsolved, although we recently found that inhibin betaA-subunit, activin A, activin receptor type IA, type IB, type IIA, type IIB, ..
  6. Dansonka Mieszkowska A, Ludwig A, Kraszewska E, Kupryjanczyk J. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet. 2006;70:594-604 pubmed
    ..002), while tumours from the UK shared the 273(CYS) codon (80%, p < 0.001). Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights...
  7. Aoki D, Suzuki N, Susumu N, Noda T, Suzuki A, Tamada Y, et al. Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma. Hum Cell. 2005;18:143-6 pubmed
    A cell line, designated as RMG-V, was established from a patient with clear cell adenocarcinoma of the ovary...
  8. Herawi M, Drew P, Pan C, Epstein J. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum Pathol. 2010;41:594-601 pubmed publisher
    Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell ..
  9. Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, et al. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int. 2009;59:19-27 pubmed publisher
    ..In the present study, which compared clear cell adenocarcinoma (CLA) of the ovary with serous adenocarcinoma (SEA), the immunohistochemical expression of mTOR, ..

More Information

Publications69

  1. Guiou M, Hall W, Konia T, Scudder S, Leiserowitz G, Ryu J. Primary clear cell adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy: a case report. Int J Gynecol Cancer. 2008;18:1118-21 pubmed
    Primary clear cell adenocarcinoma of the rectovaginal septum is rare and typically emerges in the setting of endometriosis...
  2. Sun K, Huan Y, Unger P. Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med. 2008;132:1417-22 pubmed publisher
  3. Ho C, Lai H, Huang S, Chien T, Lin M, Chang S. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest. 2010;40:310-8 pubmed publisher
    Specific tumour suppressor genes with promoter methylation in ovarian clear cell adenocarcinoma (OCCA) can be one important epigenetic mark distinguishing OCCA from ovarian serous adenocarcinoma (OSA), benign endometriotic cysts and ..
  4. Abascal Junquera J, Cecchini Rosell L, Martos Calvo R, Salvador Lacambra C, Celma Domenech A, de Torres I, et al. [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management]. Actas Urol Esp. 2007;31:411-6 pubmed
    To present a new case of a primary clear cell adenocarcinoma of the urethra and its surgical management.
  5. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T. Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci. 2007;98:1586-91 pubmed
    ..The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior...
  6. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology. 2010;56:740-9 pubmed publisher
    To identify the key cell-cycle dysregulations in the development of endometriosis-associated ovarian clear cell adenocarcinoma (CCA).
  7. Adams B, Sawhney R, Sheil A, Chaudhary U. A rare case of clear cell adenocarcinoma of the bladder with unique pathological features. Am J Med Sci. 2007;333:63-5 pubmed
    ..While specific criteria for a diagnosis of clear cell adenocarcinoma have not been defined, there are consistent staining patterns suggested for characterization...
  8. Suzuki N, Higashiguchi A, Hasegawa Y, Matsumoto H, Oie S, Orikawa K, et al. Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell. 2005;18:147-55 pubmed
    Among various types of surface epithelial ovarian carcinoma, clear cell adenocarcinoma often has a particularly poor prognosis even when diagnosed in stage I...
  9. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep. 2008;20:1299-303 pubmed
    Ovarian clear cell adenocarcinoma has low sensitivity to platinum drugs. The molecular-biological mechanism of the low sensitivity has not been clarified...
  10. Rauh Hain J, Penson R. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008;18:934-6 pubmed
    Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC)...
  11. Matsuo K, Alonsozana E, Eno M, Rosenshein N, Im D. Primary peritoneal clear cell adenocarcinoma arising in previous abdominal scar for endometriosis surgery. Arch Gynecol Obstet. 2009;280:637-41 pubmed publisher
    ..Endometriosis-associated ovarian cancer arising from the surgical incision site is an unusual clinical entity...
  12. Matsuoka T, Sugi K, Matsuda E, Umemori Y, Okabe K, Hirasawa K, et al. [Clear cell adenocarcinoma with acomponent of well-differentiated fetal adenocareinoma; report of a case]. Kyobu Geka. 2006;59:867-70 pubmed
    ..Histopathologically, the tumor was diagnosed as clear cell adenocarcinoma with a component of well-differentiated fetal adenocarcinoma (WDFA), pT2N0M0, stage IB...
  13. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol. 2006;94:138-43 pubmed
    There were a few reports of a large number of patients with clear cell adenocarcinoma (CCA) of the ovary because of the low incidence of CCA...
  14. Sung M, Zhang S, MacLennan G, Lopez Beltran A, Montironi R, Wang M, et al. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res. 2008;14:1947-55 pubmed publisher
    b>Clear cell adenocarcinoma in the urinary tract is a rare entity with an appearance resembling its counterpart in the female genital tract...
  15. Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N, et al. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 2009;19:1347-52 pubmed publisher
    ..However, the role of HOXA10 in the carcinogenesis of ovarian clear cell adenocarcinoma (OCCA) has not been established...
  16. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009;22:824-32 pubmed publisher
    ..To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and ..
  17. Nakazato T, Kanuma T, Tamura T, Faried L, Aoki H, Minegishi T. Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:426-32 pubmed
    b>Clear cell adenocarcinoma of the ovary has a poor prognosis due to chemoresistance and early metastasis to the lymph nodes. It also can result in endometriosis and is the second most frequent type of ovarian cancer in Japan...
  18. Tong G, Weeden E, Hamele Bena D, Huan Y, Unger P, Memeo L, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?. Am J Surg Pathol. 2008;32:1380-7 pubmed publisher
    ..We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), ..
  19. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010;20:240-7 pubmed
    ..Little data are available, however, on the use of this regimen in patients with clear cell adenocarcinoma of the ovary (CCC)...
  20. Nagai Y, Inamine M, Hirakawa M, Kamiyama K, Ogawa K, Toita T, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:469-73 pubmed
    The aim of this study was to clarify the efficacy of postoperative whole abdominal radiotherapy (WAR) for ovarian clear cell adenocarcinoma (OCCA).
  21. Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K, et al. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol. 2007;31:999-1006 pubmed
    We occasionally encountered clear cell adenofibromatous (CCAF) components coexisting in the ovarian clear cell adenocarcinoma (CCA)...
  22. Higashiguchi A, Yamada T, Susumu N, Mori T, Suzuki A, Aoki D, et al. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. Cancer Sci. 2007;98:387-91 pubmed
    ..have demonstrated that hepatocyte nuclear factor-1beta (HNF-1beta) is expressed specifically in clear cell adenocarcinoma (CCC)...
  23. Takeuchi M, Matsuzaki K, Nishitani H. Clear cell adenocarcinoma of the female urethra: magnetic resonance imaging. J Comput Assist Tomogr. 2009;33:142-4 pubmed publisher
    b>Clear cell adenocarcinoma of the female urethra is a rare malignant tumor arising from urethral diverticulum or paraurethral ducts and glands, and extends to the submucosa surrounding the urethra...
  24. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res. 2009;15:1473-80 pubmed publisher
    ..In this study, we investigated whether expression of these microtubule-associated factors affects the therapeutic efficacy of taxane-based chemotherapy in ovarian clear cell adenocarcinoma.
  25. Tan D, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol. 2007;60:355-60 pubmed
  26. Tazi H, Tazi K, Ouali M, Koutani A, Hachimi M, Lakrissa A. [Urinary bladder mesonephric clear cell adenocarcinoma]. Prog Urol. 2004;14:1209-12 pubmed
    ..With a follow-up of 30 months, the patient is still alive without recurrence or metastasis. The etiopathogenic, histologic and therapeutic aspects of this tumour are reviewed...
  27. Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma. Oncol Rep. 2004;12:805-10 pubmed
    ..Since considerable cases of normal kidney are hypermethylated, contribution of the RASSF1A for the development and progression of kidney cancer may be more complex than expected...
  28. Takemoto Y, Yano H, Momosaki S, Ogasawara S, Nishida N, Kojiro S, et al. Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Clin Cancer Res. 2004;10:7418-26 pubmed
    We examined the antiproliferative effect of IFN-alphaCon1 and its mechanism on ovarian clear cell adenocarcinoma in vitro and in vivo.
  29. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer. 2006;16:52-6 pubmed
    The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated...
  30. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer. 2006;16:986-90 pubmed
    ..97, 95% CI 1.01-3.87, P= 0.048). The estimated median survival was 50.66 months (95% CI 46.12-55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease...
  31. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz R, Mok S. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2006;101:71-5 pubmed
    ..In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary. Furthermore, we analyzed the expression of cyclin D1 and p27, and investigated the correlation among all these variables...
  32. Marquez R, Baggerly K, Patterson A, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-26 pubmed
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  33. Kosem M, Sengül E. Clear cell adenocarcinoma of the urinary bladder. Scand J Urol Nephrol. 2005;39:89-92 pubmed
    b>Clear cell adenocarcinoma of the lower urinary tract, and particularly of the bladder, is a rare neoplasm and its histogenesis remains obscure...
  34. Hartmann A, Junker K, Dietmaier W, Schröder S, Lopez D, Hofstadter F, et al. Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol. 2006;37:117-20 pubmed
    ..Previous case reports suggest the possibility of nephrogenic metaplasia progressing to clear cell adenocarcinoma, but a malignant potential of nephrogenic metaplasia is generally not acknowledged...
  35. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. 2005;99:427-31 pubmed
    ..To investigate the lymph node sites most susceptible to involvement relative to primary tumor histology in ovarian cancer...
  36. Kurian A, Balise R, McGuire V, Whittemore A. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol. 2005;96:520-30 pubmed
    ..The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes...
  37. Goto K, Takeuchi Y, Yakihara A, Kotsuji F. Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecol Oncol. 2005;97:976-9 pubmed
    A multiple primary invasive carcinoma of the cervix is a rare condition and is seldom composed of squamous cell carcinoma and clear cell adenocarcinoma.
  38. Creasman W, Kohler M, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-6 pubmed
    ..The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer...
  39. Mahdavi A, Shamshirsaz A, Peiretti M, Zakashansky K, Idrees M, Nezhat F. Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review. J Minim Invasive Gynecol. 2006;13:237-41 pubmed
    Vaginal clear cell adenocarcinoma arising from pelvic endometriosis has not been reported in the literature...
  40. Ho C, Huang Y, Chen T, Huang S, Liu F, Chang Chien C, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004;94:197-203 pubmed
  41. Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschi S, et al. Risk factors for different histological types of ovarian cancer. Int J Gynecol Cancer. 2004;14:431-6 pubmed
    ..7) and endometrioid (OR = 0.8) ovarian cancers but not for mucinous (OR = 1.4) and other histologies (OR = 1.6). Finally, our results on dietary fat intake did not show substantial differences in all histological types of ovarian cancer...
  42. Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2004;94:735-9 pubmed
    ..of the expression of HER-2/neu as a prognostic factor, we retrospectively examined its overexpression rates chiefly in ovarian clear cell adenocarcinoma (CCA) and their relationships with FIGO stage, lymph node metastasis, and prognosis.
  43. Tsuda H, Bandera C, Birrer M, Hashiguchi Y, Berkowitz R, Mok S. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology. 2004;67:291-9 pubmed
    ..The purpose of this study is to compare DNA, mRNA and protein levels of the cyclin E between clear cell (CC) and serous (SC) ovarian carcinomas, and evaluate the relationship between cyclin E and p53 status...
  44. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol. 2005;97:893-7 pubmed
    The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for ovarian clear cell adenocarcinoma (OCCA).
  45. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer. 2005;104:1924-30 pubmed
    Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among human epithelial ovarian cancers...
  46. Nagle C, Olsen C, Webb P, Jordan S, Whiteman D, Green A. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer. 2008;44:2477-84 pubmed publisher
    ..Endometrioid and clear cell ovarian cancers have some shared as well as some distinct risk factors, and therefore should be considered separately in studies of ovarian cancer. ..
  47. O Sullivan Mejia E, Massey H, Faquin W, Powers C. Hyalinizing clear cell carcinoma: report of eight cases and a review of literature. Head Neck Pathol. 2009;3:179-85 pubmed publisher
    ..Cells were also positive for periodic acid-Schiff and negative for mucin. The important clinicopathologic features and the differential diagnoses of HCCC, as well as a review of the literature are discussed...
  48. Tsai H, Huang W, Chen C, Chiang M, Chao K, Shen S, et al. Two- and three-dimensional transvaginal Doppler ultrasound analysis of urethral clear cell carcinoma. Ultrasound Obstet Gynecol. 2007;29:713-6 pubmed
  49. Verloop J, van Leeuwen F, Helmerhorst T, de Kok I, van Erp E, van Boven H, et al. Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters. Gynecol Oncol. 2017;144:305-311 pubmed publisher
    Women exposed to diethylstilbestrol in utero (DES) have an increased risk of clear cell adenocarcinoma (CCA) of the vagina and cervix, while their risk of non-CCA invasive cervical cancer is still unclear...
  50. Darb Esfahani S, Wirtz R, Sinn B, Budczies J, Noske A, Weichert W, et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer. 2009;16:1229-39 pubmed publisher
  51. Wanapirak C, Srisupundit K, Tongsong T. Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses. Asian Pac J Cancer Prev. 2006;7:407-10 pubmed
    ..To determine the sensitivity and specificity of a scoring system for distinguishing between benign and malignant adnexal masses and to detect threshold scores for prediction of malignant ovarian tumors...
  52. Leitao M, Kehoe S, Barakat R, Alektiar K, Gattoc L, Rabbitt C, et al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2008;111:244-8 pubmed publisher
    ..The rate of HR uterine pathology is 4% if no cancer or myoinvasion is identified on frozen section and 18% if myoinvasion up to 50% is identified. ..
  53. Davidson B, Trope C, Wang T, Shih I. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103:814-9 pubmed
    ..However, its clinical role in ovarian cancer effusions is not clear. In the present study, we assessed the clinical significance of Rsf-1 overexpression in ovarian carcinoma effusions...
  54. Rahemtullah A, Oliva E. Nephrogenic adenoma: an update on an innocuous but troublesome entity. Adv Anat Pathol. 2006;13:247-55 pubmed
    ..Clinicopathologic correlation with careful attention to morphology remains the pillar in establishing the correct diagnosis...
  55. Shih C, Huang C, Chi C, Lin J, Pan C. CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis. J Chin Med Assoc. 2010;73:40-3 pubmed
    ..Here, we present a case of clear cell adenocarcinoma arising from the upper ureter and renal pelvis of a postmenopausal woman with a ureteral stone...
  56. Dansonka Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet. 2010;11:20 pubmed publisher
    ..PALB2 protein was recently identified as a partner of BRCA1 and BRCA2 which determines their proper function in DNA repair...
  57. Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2008;18:937-42 pubmed
    ..Another strategy including molecular-targeting therapy is warranted for the treatment of recurrent or refractory CCC...
  58. Sueblinvong T, Manchana T, Khemapech N, Triratanachat S, Termrungruanglert W, Tresukosol D. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer. Asian Pac J Cancer Prev. 2007;8:502-6 pubmed
    ..Disease free survival and overall survival did not statistically differ between those with lesions positive or negative for HER-2/neu overexpression...
  59. Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, et al. Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull. 2008;31:1316-20 pubmed
    ..These results indicated that NDRG2 might play an important role in the carcinogenesis and development of CCRCC and may function as a tumor suppressor in CCRCC...
  60. Arab M, Khayamzadeh M, Mohit M, Hosseini M, Anbiaee R, Tabatabaeefar M, et al. Survival of ovarian cancer in Iran: 2000-2004. Asian Pac J Cancer Prev. 2009;10:555-8 pubmed
    ..The aim of this study was to estimate the 5-year survival of ovarian cancer in Iran between 2000 and 2004, according to age and histology...